AKT1 and non-small cell lung carcinoma: On the other hand, icotinib was also found capable of suppressing the Akt signaling pathway activation in human NSCLC cells (24), and over-expressed miR-22 can down-regulate phosphatase and tensin homolog and activate phosphoinositide 3-kinase (PI3K)/AKT pathway (25), showing that miR-22 may affect the icotinib efficacy in NSCLC through the Akt signaling pathway.